Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism

BMC Infectious Diseases

Maurizio Zazzi¹  Cinzia Caudai¹  Antonella Pirazzoli²  Michele Mancini²  Ilaria Vicenti¹  Andrea Rosi¹  Francesco Saladini¹  Angelo Materazzi¹  Genny Meini¹ 

[1] Department of Medical Biotechnologies, University of Siena, Siena, Italy;ViiV Healthcare, Verona, Italy

关键词: Shipment;    Storage;    Stability;    Whole blood;    DNA;    Coreceptor tropism;    V3 region;    HIV-1;   

Others  :  1145626
DOI  :  10.1186/1471-2334-13-508

 received in 2013-05-07, accepted in 2013-10-02,  发布年份 2013

【 摘 要 】

Background

Maraviroc is an HIV-1 coreceptor antagonist that has shown good efficacy and tolerability in treatment-naive and treatment-experienced patients harboring CCR5-tropic virus. The use of Maraviroc in treatment simplification in patients with suppressed plasma HIV-1 RNA requires analysis of HIV-1 DNA. Coreceptor tropism testing is often performed remotely at reference laboratories. In this study paired whole blood stored at + 4°C and at−20°C were compared as a source for genotypic coreceptor tropism testing.

Methods

Two hundred paired whole blood samples from different patients were analysed. Each sample was stored in two different conditions: one aliquot was stored at−20°C until spin column DNA extraction (WB20) and one aliquot was stored at +4°C for two weeks and then placed at room temperature (22-24°C) for two days before DNA extraction (WB4). Subsequently, a fragment encompassing the HIV-1 gp120 V3 domain was amplified by a singlicate nested PCR followed by triplicate nested PCR in the negative samples. A randomly selected panel of 20 paired WB4 and WB20 duplicate amplification products were sequenced and coreceptor tropism was inferred by geno2pheno [coreceptor].

Results

WB20 yielded a higher amount of DNA than WB4 (median [IQR] values 332.5 ng/μl [117.5-401] and 107 ng/μl [56.6-318], respectively; P < 0.001). However, the DNA purity was higher for WB4 than for WB20 (median distance from the optimal OD_260/280 ratio, 0.14 [0.07-0.79] and 0.96 [0.36-1.10], respectively; P < 0.0001). The number of samples successfully amplified was 152 (76.0%) for WB20 and 155 (77.5%) for WB4 with the first PCR and 179 (89.5%) for WB20 and 181 (90.5%) for WB4 (P = ns) following subsequent triplicate analysis. The inferred coreceptor tropism was concordant in 18 out of 20 paired WB4 and WB20 samples. Two samples yielded discordant results, consistent with the discordance rate within duplicates from the same sample source (2/20 with WB4 and 1/20 with WB20) due to the inherent gp120 V3 variability.

Conclusions

Storing whole blood at +4°C for up to two weeks and shipping at room temperature is a convenient method for obtaining HIV-1 gp120 V3 sequence information via testing at a remote laboratory in patients with suppressed viremia.

【 授权许可】

   
2013 Meini et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Poveda E, Alcamí J, Paredes R, Córdoba J, Gutiérrez F, Llibre JM, Delgado R, Pulido F, Iribarren JA, García Deltoro M, Hernández Quero J, Moreno S, García F: Genotypic determination of HIV tropism-clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev 2010, 12:135-148.
• [2]Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
• [3]Vandekerckhove LP, Wensing AM, Kaiser R, et al.: European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011, 11:394-407.
• [4]Soriano V, Perno CF, Kaiser R, et al.: When and how to use maraviroc in HIV-infected patients. AIDS 2009, 23:2377-2385.
• [5]Wasmuth JC, Rockstroh JK, Hardy WD: Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opin Drug Saf 2012, 11:161-174.
• [6]Seclén E, Del Mar González M, De Mendoza C, Soriano V, Poveda E: Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 2010, 65:1493-1496.
• [7]Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Cauda R, Zazzi M, De Luca A: Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 2010, 7:56. BioMed Central Full Text
• [8]Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM: Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 2011, 12:544-552.
• [9]Vitiello P, Brudney D, MacCartney M, Garcia A, Smith C, Marshall N, Johnson M, Geretti AM: Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load. Intervirology 2012, 55:172-178.
• [10]Bonjoch A, Pou C, Pérez-Álvarez N, Bellido R, Casadellà M, Puig J, Noguera-Julian M, Clotet B, Negredo E, Paredes R: Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. J Antimicrob Chemother 2013, 68:1382-1387.
• [11]Symons J, Vandekerckhove L, Paredes R, Verhofstede C, Bellido R, Demecheleer E, Van Ham PM, Van Lelyveld SF, Stam AJ, Van Versendaal D, Nijhuis M, Wensing AM: Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. Clin Microbiol Infect 2012, 18:606-612.
• [12]Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R: Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007, 25:1407-1410.
• [13]Maniatis T, Fritsch EF, Sambrook J: Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory; 1982.
• [14]Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS: Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011, 204:135-138.